Review Article
Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease
Table 3
Targeted therapies evaluated in clinical trials for thyroid cancer.
| Drug | VEGFR1 | VEGFR2 | VEGFR3 | RET | BRAF | Other | Response; PFS | Citation |
| Axitinib | X | X | X | | | | 31% PR; 18 mos (MTC included) | Cohen et al. [91, 99] |
| Motesanib | X | X | X | X | | | 14% PR; 9 mos | Sherman et al. [97] |
| Sorafenib | | X | X | X | X | | 13–32% PR; PFS 10–21 mos | Kloos et al. [86], Gupta-Abramson et al. [87], Cabanillas et al. [88] |
| Sunitinib | X | X | X | X | | | 28% CR + PR; TTP 13 mos |
Carr et al. [93] |
| Pazopanib | X | X | X | X | | | 49% PR; PFS 12 mos |
Bible et al. [94] |
| Lenvatinib | X | X | X | X | | FGFR | 50% PR; PFS 13 mos | Sherman et al. [105] |
| Cabozantinib | X | X | | X | | c-MET | 53% PR; PFS n/a |
Cabanillas et al. [101] |
|
|
PR: partial response, SD: stable disease, TTP: time to progression, PFS: progression-free surivival, n/a: not available, and mos: months.
|